The solute carrier SLC7A1 may act as a protein transporter at the blood-brain barrier.

Autor: Kurtyka M; Institute for Pathobiochemistry, University Medical Center Mainz, Mainz, Germany., Wessely F; UK Dementia Research Institute, Cardiff University, Cardiff, United Kingdom., Bau S; Pathology & Imaging, Novo Nordisk A/S, Måløv, Denmark., Ifie E; Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom., He L; Department of Immunology, Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden., de Wit NM; Amsterdam UMC location Vrije Universiteit Amsterdam, Department of Molecular Cell Biology and Immunology, Amsterdam, the Netherlands; Amsterdam Neuroscience, Amsterdam, the Netherlands., Pedersen ABV; Department of Pharmacy, University of Copenhagen, Copenhagen, Denmark., Keller M; Institute for Pathobiochemistry, University Medical Center Mainz, Mainz, Germany., Webber C; UK Dementia Research Institute, Cardiff University, Cardiff, United Kingdom., de Vries HE; Amsterdam UMC location Vrije Universiteit Amsterdam, Department of Molecular Cell Biology and Immunology, Amsterdam, the Netherlands; Amsterdam Neuroscience, Amsterdam, the Netherlands., Ansorge O; Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom., Betsholtz C; Department of Immunology, Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden; Department of Medicine (Huddinge), Karolinska Institutet, Huddinge, Sweden., De Bock M; Neuroscience Discovery, Janssen Research & Development, Janssen Pharmaceutica, Beerse, Belgium., Chaves C; Rare and Neurologic Diseases Research Therapeutic Area, Sanofi, Chilly Mazarin, France., Brodin B; Department of Pharmacy, University of Copenhagen, Copenhagen, Denmark., Nielsen MS; Department of Biomedicine, Faculty of Health, Aarhus University, Aarhus, Denmark., Neuhaus W; Austrian Institute of Technology GmbH, Vienna, Austria; Department of Medicine, Faculty of Medicine and Dentistry, Danube Private University, Krems, Austria., Bell RD; Ascidian Therapeutics Inc., Boston, USA., Letoha T; Pharmacoidea Ltd., Szeged, Hungary., Meyer AH; AbbVie Deutschland GmbH & Co. KG, Quantitative, Translational & ADME Sciences, Ludwigshafen, Germany., Leparc G; Boehringer Ingelheim Pharma GmbH & Co. KG, Translational Medicine & Clinical Pharmacology, Biberach, Germany., Lenter M; Boehringer Ingelheim Pharma GmbH & Co. KG, Drug Discovery Sciences, Biberach, Germany., Lesuisse D; Rare and Neurologic Diseases Research Therapeutic Area, Sanofi, Chilly Mazarin, France., Cader ZM; Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom., Buckley ST; Global Research Technologies, Novo Nordisk A/S, Måløv, Denmark., Loryan I; Department of Pharmacy, Uppsala University, Uppsala, Sweden., Pietrzik CU; Institute for Pathobiochemistry, University Medical Center Mainz, Mainz, Germany. Electronic address: pietrzik@uni-mainz.de.

Publikováno v: European journal of cell biology [Eur J Cell Biol] 2024 Jun; Vol. 103 (2), pp. 151406. Date of Electronic Publication: 2024 Mar 21.

Additional file 4 of Exploring ITM2A as a new potential target for brain delivery

Autor: Cegarra, C��line, Chaves, C., D��on, C., Do, T. M., Dumas, B., Frenzel, A., Kuhn, P., Roudieres, V., Guillemot, J. C., Lesuisse, D.

Additional file 4: Figure S4. Detection limit of mouse ITM2A by western blot in HEK293 overexpressing mITM2A. Signal is quantified with MultiGauge v3.0. Housekeeping protein is ��-tubulin in orange and protein of interest is ITM2A in blue.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::736a81d37c771dcda360d0a339626129

Additional file 1 of Exploring ITM2A as a new potential target for brain delivery

Autor: Cegarra, C��line, Chaves, C., D��on, C., Do, T. M., Dumas, B., Frenzel, A., Kuhn, P., Roudieres, V., Guillemot, J. C., Lesuisse, D.

Additional file 1: Figure S1. Clonal selection of stable HEK293 overexpressing ITM2A. After fluorescence selection, better clones were confirmed by Western Blot. Clones with higher expression and higher luminescent signal were selected. Selected clon

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1017eaf230441462c985a7e895505eb4

An innovative strategy to identify new targets for delivering antibodies to the brain has led to the exploration of the integrin family.

Autor: Cegarra C; Rare and Neurologic Diseases Research Therapeutic Area, Sanofi, Chilly Mazarin, France., Cameron B; Biological Research, Sanofi, Vitry-Sur-Seine, France., Chaves C; Rare and Neurologic Diseases Research Therapeutic Area, Sanofi, Chilly Mazarin, France., Dabdoubi T; Biological Research, Sanofi, Vitry-Sur-Seine, France., Do TM; Rare and Neurologic Diseases Research Therapeutic Area, Sanofi, Chilly Mazarin, France., Genêt B; Integrated Drug Discovery, Sanofi, Vitry-Sur-Seine, France., Roudières V; Rare and Neurologic Diseases Research Therapeutic Area, Sanofi, Chilly Mazarin, France., Shi Y; Histology, Translational Sciences, Sanofi, Vitry-Sur-Seine, France., Tchepikoff P; Histology, Translational Sciences, Sanofi, Vitry-Sur-Seine, France., Lesuisse D; Rare and Neurologic Diseases Research Therapeutic Area, Sanofi, Chilly Mazarin, France.

Publikováno v: PloS one [PLoS One] 2022 Sep 15; Vol. 17 (9), pp. e0274667. Date of Electronic Publication: 2022 Sep 15 (Print Publication: 2022).

Bone-targeted Src SH2 inhibitors block Src cellular activity and osteoclast-mediated resorption

Autor: Violette, S.M, Guan, W, Bartlett, C, Smith, J.A, Bardelay, C, Antoine, E, Rickles, R.J, Mandine, E, van Schravendijk, M.R, Adams, S.E, Lynch, B.A, Shakespeare, W.C, Yang, M, Jacobsen, V.A, Takeuchi, C.S, Macek, K.J, Bohacek, R.S, Dalgarno, D.C, Weigele, M, Lesuisse, D, Sawyer, T.K ^*, Baron, R

Publikováno v: In Bone 2001 28(1):54-64